Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Primary endpoint of progression-free survival not met in the phase III VOYAGER study in patients with molecularly unselected gastrointestinal stromal tumour
Findings from the CHRYSALIS study in patients with non-small cell lung cancer after progression on platinum-based chemotherapy
Phase III study results point to noninferiority of acalabrutinib, while it provides improved safety in patients with previously treated chronic lymphocytic leukaemia
KEYNOTE-522 study was the basis for approval in the neoadjuvant and adjuvant setting
Update of recommendations for monitoring patients
It is intended for the treatment of leukaemia and gastrointestinal stromal tumours
Data from a study across the world point to a substantial number of cancer cases that could potentially be avoided
Women in this age category qualify for clinical genetic testing and magnetic resonance imaging screening
Withdrawal concerns the application to extend the use of atezolizumab to include the treatment of early or locally advanced triple-negative breast cancer
The approval concerns management of patients with no MSI-H/dMMR tumours
Findings from a prospective study from the St Jude Lifetime Cohort
Results of the second interim analysis of the KEYNOTE-629 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
